This company listing is no longer active
Cantargia Valuation
Is CANTA BTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CANTA BTA?
Other financial metrics that can be useful for relative valuation.
| What is CANTA BTA's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | kr512.49m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -0.2x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CANTA BTA's PB Ratio compare to its peers?
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | n/a | ||
INIT Initiator Pharma | 32.7x | 209.8% | kr489.0m |
IMMU Mendus | 0.9x | 79.3% | kr417.3m |
IVACC Intervacc | 1.6x | 49.9% | kr409.0m |
XBRANE Xbrane Biopharma | 1.4x | 108.9% | kr542.9m |
CANTA BTA Cantargia | 1.2x | 79.2% | kr512.5m |
Price-To-Book vs Peers: Insufficient data to calculate CANTA BTA's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Earnings Ratio vs Industry
How does CANTA BTA's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: CANTA BTA is good value based on its Price-To-Book Ratio (1.2x) compared to the Swedish Biotechs industry average (2.5x)
Price to Book Ratio vs Fair Ratio
What is CANTA BTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate CANTA BTA's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CANTA BTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CANTA BTA (SEK5.01) is trading below our estimate of fair value (SEK38.86)
Significantly Below Fair Value: CANTA BTA is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.